Journal: Blood cancer journal
This publication reviews advancements in frontline treatment for newly diagnosed, transplant-eligible multiple myeloma patients. It highlights the standard use of high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) as of 2025.
The article emphasizes:
- Integration of induction therapy using quadruplet drug combinations prior to high-dose melphalan.
- Recommendation of lenalidomide maintenance until disease progression.
These treatment strategies, developed through phase 3 trials by academic groups, have significantly improved median overall survival from 5 years in the 1990s to over 15 years today.
The article also details the contributions of the French myeloma cooperative group, Intergroupe Francophone du Myélome (IFM), in advancing care for this patient population.